Journal
STROKE
Volume 42, Issue 9, Pages 2633-2635Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.111.618215
Keywords
acute stroke; inflammation; neuroprotection
Categories
Funding
- National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01 NS055728, NS063965]
- Veteran Affairs Merit Review
- American Heart Association
- Medical College of Georgia Intramural Grants Program Scientist Training Program
Ask authors/readers for more resources
Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P = 0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P < 0.0001; non-tPA, P = 0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity. (Stroke. 2011;42:2633-2635.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available